Health Care • Biotechnology: Pharmaceutical Preparations
$1.53 ▲ +0.15
(+10.87%)
MKT CAP: $48.1M • VOL: 181.7K
52W L $1 52W H $2
ROARABLE / RQD
D- • 42/100
PIOTROSKI
3 / 9
ATNM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $90.0K | $0 | $81.0K |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$36.2M | -$42.1M | -$51.9M |
| Operating Margin % | -80.0% | — | -80.0% |
| Net Income (GAAP) | -$33.9M | -$38.2M | -$48.8M |
| EBITDA (Normalized) | -$36.2M | -$42.1M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$24.6M | -$33.1M | -$47.3M |
| Capital Expenditures (CapEx) | $104.0K | $11.0K | — |
| Free Cash Flow (FCF) | -$24.7M | -$33.1M | -$47.3M |
| FCF Margin % | -80.0% | — | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $48.0M | $72.9M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $7.8M | $32.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ATNM.